|ENTERPRISE PRODUCTS PARTNERS L P filed this Form 8-K on 11/14/2017|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 8, 2017
ENTERPRISE PRODUCTS PARTNERS L.P.
(Exact name of registrant as specified in its charter)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously disclosed, effective as of October 1, 2014, (i) Marquard & Bahls, AG (“M&B”) selected Dr. F. Christian Flach as M&B’s designee (the “M&B Designee”) for appointment to the board of directors (the “Board”) of Enterprise Products Holdings LLC, the general partner of Enterprise Products Partners L.P. (the “Partnership”) pursuant to the Contribution and Purchase Agreement dated as of October 1, 2014 (the “Purchase Agreement”), by and among the Partnership, Oiltanking Holding Americas, Inc. and OTB Holdco, LLC, and (ii) Dan Duncan LLC (“DDLLC”), the sole member of the Partnership’s general partner, appointed Dr. Flach as a member of the Board.
On November 8, 2017, M&B notified DDLLC and the Board that Dr. Flach has decided to resign from the Board. Dr. Flach confirmed his resignation effective as of November 10, 2017. Although M&B has indicated that it reserves the right to select a replacement M&B Designee pursuant to the Purchase Agreement, M&B has not selected a replacement at this time.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.